SEB Nordic Future Opportunity IC EURRegister to Unlock Ratings |
Performance History | 30/04/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 22.0 | 24.7 | -12.3 | 1.9 | 3.8 | |
+/-Cat | -2.8 | 8.4 | 1.2 | -6.1 | 0.1 | |
+/-B’mrk | - | - | - | - | -2.5 | |
Category: Nordic Equity | ||||||
Category Benchmark: Morningstar Nordic TME NR SEK |
Key Stats | ||
NAV 16/05/2024 | EUR 173.71 | |
Day Change | -0.48% | |
Morningstar Category™ | Nordic Equity | |
ISIN | LU2030514330 | |
Fund Size (Mil) 16/05/2024 | EUR 237.94 | |
Share Class Size (Mil) 16/05/2024 | EUR 14.10 | |
Max Initial Charge | - | |
Ongoing Charge 09/04/2024 | 0.86% |
Investment Objective: SEB Nordic Future Opportunity IC EUR |
To increase the value of your investment over time while seeking to create a positive environmental and social impact to achieve, inter alia, the long-term objectives of the Paris Agreement, VINX Benchmark Cap Net Return Index, a measure of performance of Nordic companies that does not take into account ESG factors and is not aligned with the sustainable objective of the sub-fund. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Caroline Forsberg 07/09/2022 | ||
Robert Vicsai 07/09/2022 | ||
Inception Date 22/08/2019 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ VINX Benchmark Cap NR SEK | Morningstar Nordic TME NR SEK |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for SEB Nordic Future Opportunity IC EUR | 30/04/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 9.92 |
Hexagon AB Class B | Technology | 5.47 |
AstraZeneca PLC | Healthcare | 5.36 |
Atlas Copco AB Class A | Industrials | 5.25 |
ABB Ltd | Industrials | 3.17 |
Increase Decrease New since last portfolio | ||
SEB Nordic Future Opportunity IC EUR |